Glioma clinical trials in Ohio
19 studies for Glioma are looking for participants at sites in Ohio.
Cities in Ohio
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Cleveland Clinic Taussig Cancer Center, Cleveland
- Ohio State University, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07326566Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
- Ohio State University Medical Center, Columbus
Recruiting
Ages 18 to 85 · All sexes · Updated Nov 12, 2026 · NCT06910306Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07703436Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
- University Hospitals Cleveland Medical Center, Cleveland
Recruiting
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07628647ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Cincinnati Children's Hospital, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Oct 23, 2026 · NCT06838676Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06810544Development of MRF for Characterization of Brain Tumors After Radiotherapy
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland
- Cleveland Clinic Taussig Cancer Center, Cleveland
RecruitingHealthy volunteers welcome
Ages 18 to 60 · All sexes · Updated Oct 20, 2026 · NCT06101069SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519Targeted Pediatric High-Grade Glioma Therapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT05565118A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Nationwide Children's Hospital, Colombus
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT06964737A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
- Nationwide Children's Hospital, Columbus
RecruitingPhase 1
12 Months – 39 Years · All sexes · Updated May 13, 2025 · NCT04254419From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.